Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email:

Yearly Archives: 2017

Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine

San Diego, CA, June 28, 2017 – Aegis Therapeutics announces positive Phase 2 results of DFN-02 using Intravail® technology. Dr. Reddy’s Laboratories in collaboration with Promius Pharma, LLC (a wholly owned subsidiary of DRL) is developing DFN-02, a novel intranasal migraine treatment using Intravail for the acute treatment of adults with migraine with or without […]

Opiant Pharmaceuticals, Inc. Licenses Aegis Therapeutics’ Intravail® Drug Delivery Technology

SANTA MONICA, California – June 28, 2017 – Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced a global, exclusive licensing agreement providing Opiant access to Aegis’ Intravail® drug delivery technology for all of Opiant’s opioid antagonist compounds. Financial terms were not disclosed. “We are […]

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

SAN DIEGO, May 4, 2017 /PRNewswire/ — Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, today announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration. “This trial achieved all its endpoints confirming that therapeutic doses of […]